Overview An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy Status: RECRUITING Trial end date: 2029-06-01 Target enrollment: Participant gender: Summary CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.Phase: PHASE2 Details Lead Sponsor: Shanghai Zhimeng Biopharma, Inc.